

ITW



Group Art Unit: 1651

Attorney  
Docket: 27132

Attorney  
Docket: 27132

§§§§§

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**


2

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,  
Martin O. Moynihan

Dated: June 21, 2006

**PTO/SB/08a (08-03)**

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application Number	10/759,033
Filing Date	January 20, 2004
First Named Inventor	Yair REISNER et al
Art Unit	1651
Examiner Name	unknown
Attorney Docket Number	27132

Sheet 1 of 7

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-5,175,004	12-29-1992	Matsumura	
	2	US-5,580,558	03-3-1996	Kitamura	
	3	US-5,942,435	08-24-1999	Wheeler	
	4	US-6,060,049	09-9-2000	Beschorner	
	5	US-6,140,116	10-31-2000	Dinsmore	
	6	US-2003/0096016	05-22-2003	Reisner et al.	
	7	US-2004/0136972	07-15-2004	Reisner et al.	
	8	US-2005/0226854	10-13-2005	Reisner et al.	
	9	US-6,183,734	06-6-2001	Chen et al.	
	10	US-6,024,957	02-15-2000	Lazarovits et al.	
	11	US-5,635,365	03-3-1997	Ansari et al.	
	12	US-6,194,147	02-27-2001	Baxter-Lowe et al.	
	13	US-2004/0082064	04-29-2004	Reisner et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	14	PCT WO 03/022123	03-20-2003	Reisner et al.		
	15	PCT WO 2004/078022	09-16-2004	Reisner et al.		
	16	EP 0853942	07-22-1998	Hammerman		
	17	PCT WO 00/41713	07-20-2000	Hammerman et al.		
	18	PCT WO 2004/016276	02-26-2004	Bottomley et al.		
Examiner Signature			Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/759,033	
			Filing Date	January 20, 2004	
			First Named Inventor	Yair REISNER et al	
			Group Art Unit	1651	
			Examiner Name	unknown	
Sheet	2		7	Attorney Docket Number	27132
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	19	Groth et al. "Xenotransplantation: Experimental and Clinical Aspects", Journal of Molecular Medicine, 77: 153-154, 1999.			
	20	Hammerman "Transplantation of Renal Precursor Cells: A New Therapeutic Approach", Pediatr. Nephrol., 14: 513-517, 2000.			
	21	Hammerman "Xenotransplantation of Renal Primordia", Current Opinion in Nephrology and Hypertension, 11: 11-16, 2002.			
	22	Hanto "Classification of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Diseases: Implications for Understanding Their Pathogenesis and Developing Rational Treatment Strategies", Annu. Rev. Med., 46: 381-394, 1995.			
	23	Higgins et al. "Prevention of Hyperacute Rejection by Removal of Antibodies to HLA Immediately Before Renal Transplantation", The Lancet, 348: 1208-1211, 1996.			
	24	Hyink et al. "Endogenous Origin of Glomerular Endothelial and Mesangial Cells in Grafts of Embryonic Kidneys", Am. J. Physiol., 270(Renal Fluid Electrolyte Physiol.39): F886-F899, 1996.			
	25	Itskovitz-Eldor et al. "Differentiation of Human Embryonic Stem Cells Into Embryonic Bodies Comprising the Three Embryonic Germ Layers", Molecular Medicine, 6(2): 88-95, 2000.			
	26	Kaminski et al. "Practical Approaches to Analyzing Results of Microarray Experiments", Am. J. Respir. Cell Mol. Biol., 27: 125-132, 2002.			
	27	Kaminski et al. "Global Analysis of Gene Expression in Pulmonary Fibrosis Reveals Distinct Programs Regulating Lung Inflammation and Fibrosis", Proc. Natl. Acad. Sci. USA, 97(4): 1778-1783, 2000.			
	28	Kirkpatrick et al. "Transplantation Immunology", JAMA, 268(20): 2952-2958, 1992.			
	29	Kreisel et al. "Non-Hematopoietic Allograft Cells Directly Activate CD8+ T Cells and Trigger Acute Rejection: An Alternative Mechanism of Allorecognition", Nature Medicine, 8(3): 233-239, 2002.			
	30	Lee et al. "Efficient Generation of Midbrain and Hindbrain Neurons From Mouse Embryonic Stem Cells", Nature Biotechnology, 18: 675-679, 2000.			
	31	Levite et al. "Beneficial Effects of Bone Marrow Transplantation on the Serological Manifestations and Kidney Pathology of Experimental Systemic Lupus Erythematosus", Cellular Immunology, 162: 138-145, 1995.			
	32	Li et al. "Blocking Both Signal 1 and Signal 2 of T-Cell Activation Prevents Apoptosis of Alloreactive T Cells and Induction of Peripheral Allograft Tolerance", Nature Medicine, 5(11): 1298-1302, 1999.			
	33	Lubin et al. "Engraftment of Human Peripheral Blood Lymphocytes in Normal Strains of Mice", Blood, 83(8): 2368-2381, 1994.			
	34	Lumelsky et al. "Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets", Science, 292: 1389-1394, 2001.			
	35	Marcus et al. "Human/Mouse Radiation Chimera Are Capable of Mounting A Human Primary Humoral Response", Blood, 86(1): 398-406, 1995.			
	36	Midthun et al. "Medical Management and Complications in the Lung Transplant Recipient", Mayo Clin. Proc., 72: 175-184, 1997.			
	37	Morrison et al. "Clinical Characteristics of Post-Transplant Lymphoproliferative Disorders", The American Journal of Medicine, 97: 14-24, 1994.			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/759,033	
			Filing Date	January 20, 2004	
			First Named Inventor	Yair REISNER et al	
			Group Art Unit	1651	
			Examiner Name	unknown	
Sheet	3		7	Attorney Docket Number	27132
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	38	Naveh-Many et al. "Estrogen Receptors and Biologic Response in Rat Parathyroid Tissue and C Cells", Journal of Clinical Investigation, 90: 2434-2438, 1992.			
	39	Nelson et al. "Chemokines, Chemokine Receptors, and Allograft Rejection", Immunity, 14: 377-386, 2001.			
	40	O'Regan et al. "Osteopontin (Eta-1) in Cell-Mediated Immunity: Teaching An Old Dog New Tricks", Immunology Today, 21(10): 475-478, 2000.			
	41	Oliver et al. "Metanephric Mesenchyme Contains Embryonic Renal Stem Cells", AJP - Renal Physiology, 283: 799-809, 2002.			
	42	Otonkoski et al. "Differentiation and Maturation of Porcine Fetal Islet Cells In Vitro and After Transplantation", Transplantation, 68(11): 1674-1683, 1999.			
	43	Pratt et al. "Local Synthesis of Complement Component C3 Regulates Acute Renal Transplant Rejection", Nature Medicine, 8(6): 582-587, 2002.			
	44	Reisner et al. "The Trimeric Mouse: Generating Human Monoclonal Antibodies and An Animal Model for Human Diseases", Trends in Biotechnology, 16: 242-246, 1998.			
	45	Rogers et al. "Transplantation of Rat Metanephroi Into Mice", Am. J. Physiol. Regul. Integr. Comp. Physiol., 280: R1865-R1869, 2001.			
	46	Rogers et al. "Transplantation of Metanephroi After Preservation In Vitro", The American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 281: 661-665, 2001.			
	47	Rogers et al. "Transplantation of Developing Metanephroi Into Adult Rats", Kidney International, 54: 27-37, 1998.			
	48	Rogers et al. "Transplantation of Metanephroi Across the Major Histocompatibility Complex in Rats", The American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 280: 132-136, 2001.			
	49	Schumacher et al. "Transplantation of Embryonic Porcine Mesencephalic Tissue in Patients With PD", Neurology, 54(5): 1042-1050, 2000.			
	50	Schwartz "Models of T Cell Anergy: Is There A Common Molecular Mechanism", The Journal of Experimental Medicine, 184: 1-8, 1996.			
	51	Soria et al. "Insulin-Secreting Cells Derived From Embryonic Stem Cells Normalize Glycemia in Streptozotocin-Induced Diabetic Mice", Diabetes, 49: 1-6, 2000.			
	52	Subramanian "Cell Transplantation for the Treatment of Parkinson's Disease", Seminars in Neurology, 21(1): 103-115, 2001.			
	53	Sayegh et al. "The Role of T-Cell Costimulatory Activation Pathways in Transplant Rejection", The New England Journal of Medicine, 338(25): 1813-1821, 1998.			
	54	Schuldiner et al. "Effects of Eight Growth Factors on the Differentiation of Cells Derived From Human Embryonic Stem Cells", Proc. Natl. Acad. Sci. USA, 97(21): 11307-11312, 2000.			

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/759,033
				Filing Date	January 20, 2004
				First Named Inventor	Yair REISNER et al
				Group Art Unit	1651
				Examiner Name	unknown
Sheet	4		7	Attorney Docket Number	27132
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	55	Segall et al. "Generation of Primary Antigen-Specific Human Cytotoxic T Lymphocytes in Human/Mouse Radiation Chimera", Blood, 88(2): 721-730, 1996.			
	56	Senderowicz et al. "Complete Sustained Response of A Refractory, Post-Transplantation, Large B-Cell Lymphoma to An Anti-CD22 Immunotoxin", Ann. Intern. Med., 126(11): 882-885, 1997.			
	57	Suthanthiran et al. "Renal Transplantation", The New England Journal of Medicine, 331(6): 365-376, 1996.			
	58	Tedder et al. "The Selectins: Vascular Adhesion Molecules", The FASEB Journal, 9: 866-873, 1995.			
	59	Vermeulen et al. "Quantification of Angiogenesis in Solid Human Tumours: An International Consensus on the Methodology and Criteria of Evaluation", European Journal of Cancer, 32A(14): 2474-2484, 1996.			
	60	Vincenti et al. "Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation", The New England Journal of Medicine, 338(3): 161-166, 1998.			
	61	Xie et al. "Expression, Roles, Receptors, and Regulation of Osteopontin in the Kidney", Kidney International, 60: 1645-1657, 2001.			
	62	Zuo et al. "Gene Expression Analysis Reveals Matrilysin as A Key Regulator of Pulmonary Fibrosis in Mice and Humans", Proc. Natl. Acad. Sci. USA, 99(9): 6292-6297, 2002.			
	63	Assmus et al. "Transplantation of Progenitor Celkls and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)", Circulation, 106: 3009-3017, 2002.			
	64	Braunwald "Shattuck Lecture - Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities", The New England Journal of Medicine, 337(19): 1360-1370, 1997.			
	65	Britten et al. "Infarct Remodeling After Intracoronary Progenitor Cell Treatment in Patients With Acute Myocardial Infarction (TOPCARE-AMI). Mechanistic Insights From Serial Contrast-Enhanced Magnetic Resonance Imaging", Circulation, 108: 2212-2218, 2003.			
	66	Castaing et al. "Blood Glucose Normalization Upon Transplantation of Human Embryonic Pancreas Into Beta-Cell-Deficient SCID Mice", Diabetologia, 44: 2066-2076, 2001.			
	67	Crippin "Motion - Patients With Primary Sclerosing Cholangitis Should Undergo Early Liver Transplantation: Arguments Against the Motion", Canadian Journal of Gastroenterology, 16: 700-702, 2002.			
	68	Eriksson "Heart Failure: A Growing Public Health Problem", Journal of Internal Medicine, 237: 135-141, 1995.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>			Application Number	10/759,033	
			Filing Date	January 20, 2004	
			First Named Inventor	Yair REISNER et al	
			Group Art Unit	1651	
			Examiner Name	unknown	
			Attorney Docket Number	27132	
Sheet	5		7		
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	69	Fischer et al. "Stem Cell Transplantation for Immunodeficiency", Springer Seminars in Immunopathology, 19: 479-492, 1998.			
	70	Friedrich "Bone Marrow Transplantation in Immunodeficiency Diseases", The Finnish Medical Society DUODECIM, Annals in Medicine, 28: 115-119, 1996.			
	71	Groth et al. "Splenic Transplantation in Gaucher Disease", Birth Defects: Original Article Series, IX(2): 102-105, 1973.			
	72	Horwitz "Primary Immune Deficiencies: Presentation, Diagnosis, and Management. Stem-Cell Transplantation for Inherited Immunodeficiency Disorders", Pediatric Clinics of North America, 47(6): 1371-1387, 2000.			
	73	Kane et al. "Neonatal Bone Marrow Transplantation for Severe Combined Immunodeficiency", Archives of Disease in Childhood - Fetal and Neonatal Edition, 85: 110-113, 2001.			
	74	Koerner et al. "Cardiac Transplantation: The Final Therapeutic Option for the Treatment of Heart Failure", Current Opinion in Cardiology, 15: 178-182, 2000.			
	75	Linsley et al. "CTLA-4 Is A Second Receptor for the B Cell Activation Antigen B7", Journal of Experimental Medicine, 174: 561-569, 1991.			
	76	Liu et al. "Transplantation of Spleen Cells in Patients With Hemophilia A. A Report of 20 Cases", Transplant International, 7(3): 201-206, 1994.			
	77	Medawar "Some Immunological and Endocrinological Problems Raised by the Evolution of Viviparity in Vertebrates", Symposium of the Society of Experimental Biology, 7: 320-323, 1953.			
	78	Michler et al. "Treatment of Cardiac Tumors by Orthotopic Cardiac Transplantation", Seminars in Oncology, 24(5): 534-539, 1997.			
	79	Molmenti et al. "Hepatocellular Cancer in Liver Transplantation", Journal of Hepatobiliary and Pancreatic Surgery, 8: 427-434, 2001.			
	80	Moore et al. "Stem Cell Transplantation for Autoimmune Diseases", Springer Seminars in Immunopathology, 23: 193-213, 2001.			
	81	Oliver et al. "Metanephric Mesenchyme Contains Embryonic Renal Stem Cells", American Journal of Physiology - Renal Physiology, 283: 799-809, 2002.			
	82	Otto "Lung Stem Cells", International Journal of Experimental Pathology, 78: 291-310, 1997.			
	83	Parkman "Bone Marrow Transplantation for Immunodeficiency and Metabolic Diseases", Leukemia, 7: 1100-1102, 1993.			
	84	Perin et al. "Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure", Circulation, 107: 2294-2304, 2003.			
	85	Podevin et al. "Transplantation Hépatique pour Maladie Alcoolique du Foie", Journal du Chirurgie, 138(3): 147-152, 2001.			
	86	Porter "The Graft-Versus-Tumor Potential of Allogeneic Cell Therapy: An Update on Donor Leukocyte Infusions and Nonmyeloablative Allogeneic Stem Cell Transplantation", Journal of Hematotherapy & Stem Cell Research, 10: 465-480, 2001.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/759,033
				Filing Date	January 20, 2004
				First Named Inventor	Yair REISNER et al
				Group Art Unit	1651
				Examiner Name	unknown
Sheet	6		7	Attorney Docket Number	27132
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	87	Pouzet et al. "Transplantation de Myoblastes Squelettiques Autologues Dans l'Insuffisance Cardiaque Ischémique", Journal de la Société de Biologie, 195(1): 47-49, 2001.			
	88	Samuel "Hepatitis B Virus and Liver Transplantation", Acta Gastro-Enterologica Belgica, LXIII: 197-199, 2000.			
	89	Segall et al. "Generation of Primary Antigen-Specific Human Cytotoxic T Lymphocytes in Human/Mouse Radiation Chimera", Blood, 88(2): 721-730, 1996.			
	90	Sharma et al. "Molecular Executors of Cell Death-Differential Intrarenal Expression of Fas Ligand, Fas, Granzyme B, and Perforin During Acute and/or Chronic Rejection of Human Renal Allografts", Transplantation, 62(12): 1860-1866, 1996.			
	91	Speziali et al. "Cardiac Transplantation for End-Stage Congenital Heart Defects: The Mayo Clinic Experience", Mayo Clinic Proceedings, 73(10): 923-928, 1998.			
	92	Stamm et al. "Autologous Bone-Marrow Stem-Cell Transplantation for Myocardial Regeneration", The Lancet, Research Letters, 361: 45-46, 2003.			
	93	Strauer et al. "Intrakoronare, Humane Autologe Stammzelltransplantation zur Myokardregeneration nach Herzinfarkt", Deutsche Medizinische Wochenschrift, 126: 932-938, 2001.			
	94	Strauer et al. "Repair of Infarcted Myocardium by autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans", Circulation: 106: 1913-1918, 2002.			
	95	Toungouz et al. "Hematopoietic Stem Cells: Therapeutic Applications in Autoimmune Diseases and in Solid Organ Transplantation", Advances in Nephrology, 31(Chap.18): 257-272, 2001.			
	96	Usadel et al. "Transplantation of human Fetal Pancreas. Experience in Thymusaplastic Mice and Rats and in A Diabetic Patient", Diabetes, 29(Suppl.1): 74-79, 1980.			
	97	Woolf "The Kidney: 1. Embryology", Pediatric Nephrology, 4th Ed., Section I(Chap.1): 1-19, 1999.			
	98	Dekel et al. "Engraftment of Human Early Kidney Precursors", Transplant Immunology, 12(3-4): 241-247, 2004. P.242, Col.2, § 1, Fig.2, Abstract.			
	99	Ashkar et al. "Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) Immunity", Science, 287: 860-863, 2000.			
	100	Auchincloss et al. "Xenogeneic Transplantation", Annu. Rev. Immunol., 16: 433-470, 1998.			
	101	Benhamou "Immunomodulation With CTLA4-Ig in IsletTransplantation", Transplantation, 73(1): S40-S42, 2002.			
	102	Benichou et al. "Contributions of Direct and Indirect T Cell Alloreactivity During Allograft Rejection in Mice", The Journal of Immunology, 162: 352-358, 1999.			
	103	Böcher et al. "Induction of Strong Hepatitis B Virus (HBV) Specific T Helper Cell and Cytotoxic T Lymphocyte Responses by Therapeutic Vaccination in the Trimera Mouse Model of Chronic HBV Infection", European Journal of Immunology, 31: 2071-2079, 2001.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/759,033
				Filing Date	January 20, 2004
				First Named Inventor	Yair REISNER et al
				Group Art Unit	1651
				Examiner Name	unknown
Sheet	7		7	Attorney Docket Number	27132
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	104	Boussiotis et al. "Differential Association of Protein Tyrosine Kinases With the T Cell Receptor Is Linked to the Induction of Anergy and Its Prevention by B7 Family-Mediated Costimulation", Journal of Experimental Medicine, 184: 365-376, 1996.			
	105	Briscoe et al. "The Allogeneic Response to Cultured Human Skin Equivalent in the Hu-PBL-SCID Mouse Model of Skin Rejection", Transplantation, 67(12): 1590-1599, 1999.			
	106	Cascalho et al. The Immunological Barrier to Xenotransplantation", Immunity, 14: 437-446, 2001.			
	107	Dantal et al. "Effect of Long-Term Immunosuppression in Kidney-Graft Recipients on Cancer Incidence: Randomised Comparison of Two Cyclosporin Regimens", Lancet, 351: 623-628, 1998.			
	108	Dekel et al. "Engraftment of Human Kidney Tissue in Rat Radiation Chimera: I. A New Model of Human Kidney Allograft Rejection", Transplantation, 64(11): 1541-1550, 1997.			
	109	Dekel et al. "Engraftment and Differentiation of Human Metanephroi Into Functional Mature Nephrons After Transplantation Into Mice Is Accompanied by A Profile of Gene Expression Similar to Normal Human Kidney Development", Journal of the American Society of Nephrology, 13(4): 977-990, 2002. Abstract.			
	110	Dekel et al. "Human and Porcine Early Kidney Precursors as A New Source for Transplantation", Nature Medicine, 9(1): 53-60, 2003. Table 1.			
	111	Dekel et al. "In Vivo Modulation of the Allogeneic Immune Response by Human Fetal Kidneys: The Role of Cytokines, Chemokines, and Cytolytic Effector Molecules", Transplantation, 69(7): 1470-1478, 2000.			
	112	Dekel et al. "Engraftment of Human Kidney Tissue in Rat Radiation Chimera: II. Human Fetal Kidneys Display Reduced Immunogenicity to Adoptively Transferred Human Peripheral Blood Mononuclear Cells and Exhibit Rapid Growth and Development", Transplantation, 64(11): 1550-1558, 1997.			
	113	Dekel et al. "Acute Cellular Rejection of Human Renal Tissue by Adoptive Transfer of Allogeneic Human Peripheral Blood Mononuclear Cells Into Chimeric Rats: Sequential Gene Expression of Cytokines, Chemokines and Cytolytic Effector Molecules, and Their Regulation by CTLA-4-Ig", International Immunology, 11(10): 1673-1683, 1999.			
	114	Eisen et al. "Cluster Analysis and Display of Genome-Wide Expression Pattern", Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1998.			
	115	Gritsch et al. "The Importance of Nonimmune Factors in Reconstitution by Discordant Xenogeneic Hematopoietic Cells", Transplantation, 57(6): 906-917, 1994.			
Signature				Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,